TANGO: Post-Hoc Analysis of Viral Replication for 2-Drug DTG/3TC Regimen vs 3- or 4-Drug TAF-Based Regimen Through Week 96

July 18-21, 2021; Virtual
Patients with HIV-1 RNA <40 copies/mL and target not detected outcome similar with dual DTG/3TC vs triple or quadruple TAF-based regimens.
Format: Microsoft PowerPoint (.ppt)
File Size: 230 KB
Released: July 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

person default Ariel Campos, MD Released: August 18, 2022

Learn from Dr Jonathan Appelbaum about medical challenges faced by aging people with HIV, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Released: August 17, 2022

Expert insights on HIV PrEP medications, guideline updates, and solutions to uptake barriers, from Dr Gregory Huhn and Clinical Care Options (CCO)

Gregory Huhn, MD, MPHTM Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 12, 2022 Expired: August 11, 2023

Clinical Care Options (CCO) commentary from Dr Darrell Tan on the dosing options for long-acting injectable cabotegravir plus rilpivirine for HIV treatment

Babafemi Taiwo, MBBS
Program Director
Darrell H. S. Tan, MD, FRCPC, PhD
Released: August 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings